Anti-mullerian Hormone in Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia
- Registration Number
- NCT05793463
- Lead Sponsor
- IRCCS Burlo Garofolo
- Brief Summary
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with current survival rates exceeding 90%. As cure rates improve, increasing attention is focused on survivor quality of life, including fertility. It is generally accepted that cancer treatments in childhood may interfere with gonadal function, reducing the pool of primordial follicles and consequently causing premature menopause in women. Anti-Mullerian hormone (AMH) levels is a valuable quantitative indicator of ovarian reserve, being directly related to the number of antral follicles. The evaluation of this hormone makes it possible to identify women at risk of early menopause and to propose them interventions for monitoring and preservation of oocytes, allowing girls to be able to have children once they reach adulthood. The objective of this study is to determine ovarian reserve in girls with ALL before and after treatment by means of the evaluation of the AMH assay.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 10
- Female less than 18 years of age
- Diagnosis of acute lymphoblastic leukemia
- enrollment within the first month after diagnosis
- Previous treatments with cytostatics drugs
- ALL as a second malignancy
- Syndromic patient or primary hypogonadism
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of blood AMH levels after ALL treatment 24 months after ALL diagnosis AMH levels will be evaluated in peripheral blood
Evaluation of blood AMH levels before ALL treatment Within one months from ALL diagnosis AMH levels will be evaluated in peripheral blood
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
IRCCS Burlo Garofolo
🇮🇹Trieste, Italy